Stocktoria
BioXcel Therapeutics, Inc. BTAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-03-08
BioXcel Therapeutics, Inc. statistics & valuation
Market cap$40.4M
P / S63.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -7860.0% | -2967.6% | -12448.0% | -42572.0% | — |
| Net margin | -10887.4% | -2630.1% | -12974.9% | -44201.9% | — |
| FCF margin | -8974.3% | -3178.6% | -11233.8% | -36128.0% | — |
| Return on assets | -155.6% | -155.5% | -242.9% | -80.5% | -44.7% |
| Return on equity | 73.2% | 64.0% | 316.9% | -215.9% | -48.2% |
| Debt / equity | -1.15× | -1.10× | -1.78× | 1.21× | — |
| Current ratio | 0.83 | 1.68 | 2.65 | 6.17 | 14.21 |
| Revenue growth | -71.7% | 64.2% | 268.0% | — | — |
Source: SEC EDGAR filings · CIK 0001720893 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.